An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation

Non-valvular Atrial Fibrillation Clinical Trial

Official title:

An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05565599
• Other study ID #: CL-0043
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 21, 2022
• Est. completion date: September 2029

Study information

• Verified date: August 2023
• Source: Laminar, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an early feasibility study is to evaluate the safety and effectiveness of the Laminar Left Atrial Appendage Closure System to treat patients with non-valvular atrial fibrillation that cannot take, or a have a reason to seek an alternative, to anticoagulant medications.

Description:

Left atrial appendage closure (LAAC) is an approved therapy for stroke prevention in atrial fibrillation patients who are recommended for chronic oral anticoagulation therapy (OAC), but are non-eligible or have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulants in accordance with evidence-based decision-making criteria and current scientific guidelines. The objective of this study is to evaluate the safety and effectiveness of the Laminar Left Atrial Appendage Closure System to treat patients with non-valvular atrial fibrillation who are deemed appropriate for LAAC to reduce the risk of stroke and systemic embolism. Patients will be followed for 5 years after the procedure.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 45
• Est. completion date: September 2029
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Documented non-valvular AF, defined as AF (paroxysmal, persistent, or permanent) in the absence of moderate-to-severe mitral stenosis or a mechanical heart valve.

2. Subject =18 years old.

3. CHA2DS2-VASc score = 2 in men and = 3 in women.

4. Subject is recommended for chronic oral anticoagulation therapy (OAC) but is not eligible or has an appropriate rationale to seek a non-pharmacologic alternative to chronic OAC.

5. Subject deemed appropriate for LAA closure by the Site Heart Team using an evidenced based decision-making tool.

6. Subject eligible for the protocol-specified post-procedural antithrombotic regimen.

7. Subject or Legally Authorized Representative informed of the nature of the study, is willing and able to comply with the protocol, and has provided written informed consent per Institutional Review Board (IRB) requirements.

Exclusion Criteria:

1. Single episode, transient, or reversible AF (e.g., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures).

2. Stroke or transient ischemic attack within 90 days before the index procedure.

3. Myocardial infarction or unstable angina within 90 days before the index procedure.

4. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2, or dialysis at the time of screening.

5. Active infection with bacteremia.

6. Confirmed COVID-19 infection within 10 days before the index procedure. Coexisting Cardiovascular Disease

7. Cardiac tumor

8. History of mitral valve or other severe cardiac valvular disease requiring intervention or presence of prosthetic mechanical valve.

9. Medical condition (other than AF) that mandates chronic oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or mechanical heart valve).

10. Severe heart failure (New York Heart Association Class IV).

11. Symptomatic carotid artery disease (>50% diameter reduction with prior ipsilateral stroke or TIA) or asymptomatic carotid artery disease (diameter reduction of >70%). Previous or Planned Interventions

12. Previous AF ablation procedure in the 90 days before the index procedure date or need for AF ablation to be performed in less than 90 days after the index procedure.

13. Recent (within 30 days before the index procedure) or planned (within 60 days after the index procedure) cardiac or non-cardiac interventional or surgical procedure.

14. Intracardiac thrombus or dense spontaneous echo contrast visualized by TEE within 2 days before the index procedure.

15. Left ventricular ejection fraction (LVEF) <30%.

16. Circumferential pericardial effusion >10 mm or symptomatic pericardial effusion, signs or symptoms of acute or chronic pericarditis, or evidence of tamponade physiology.

17. Complex atheroma with mobile plaque of the aorta.

18. Interatrial communication, atrial septal defect, or patent foramen ovale that warrants closure.

19. Vascular access precluding delivery of implant with catheter-based system

20. Presence of inferior vena cava (IVC) filter that would interfere with Laminar sheath insertion.

21. Subject unable to undergo general anesthesia.

22. Subject with condition which precludes adequate transesophageal echocardiographic (TEE) assessment.

23. Known allergy, hypersensitivity or contraindication to aspirin, heparin, or device materials (e.g., nickel, titanium).

24. Contrast sensitivity that cannot be adequately pre-medicated.

25. Bleeding diathesis or coagulopathy

26. Thrombocytopenia (platelet count <75,000 cells/mm3), thrombocytosis (>700,000 cells/mm3), or leukopenia (white blood cell count <3,000 cells/mm3).

27. Pregnant or nursing and those who plan pregnancy in the period up to 1 year following the index procedure. Subjects of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days before index procedure.

28. Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 1 year.

29. Current participation in another investigational drug or device study that in the opinion of the investigator could confound the data interpretation.

Related Conditions & MeSH terms

• Atrial Fibrillation
• Non-valvular Atrial Fibrillation

Intervention

Device:
• Left Atrial Appendage Closure
Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System.

Locations

Country	Name	City	State
United States	St. Bernards Medical Center	Jonesboro	Arkansas
United States	Scripps Health	La Jolla	California
United States	Columbia U. Medical Center / NY Presbyterian Hospital	New York	New York
United States	The Mount Sinai Hospital	New York	New York
United States	UC Davis Medical Center	Sacramento	California
United States	Los Robles Hospital & Medical Center	Thousand Oaks	California
United States	Tucson Medical Center	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Laminar, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite Adverse Events	Composite rate of all-cause mortality, stroke, systemic embolism, life threatening or major bleeding (BARC Type 3 or 5), pericardial effusion requiring drainage, device embolization, and device- or procedure-related events requiring open cardiac surgery or major endovascular intervention.	45 days
Primary	Composite Adverse Events	Composite rate of all-cause mortality, stroke, systemic embolism, life threatening or major bleeding (BARC Type 3 or 5), pericardial effusion requiring drainage, device embolization, and device- or procedure-related events requiring open cardiac surgery or major endovascular intervention.	12 months
Primary	LAA Closure Rate	Rate of LAA closure defined by peri-device flow = 3mm in width per TEE evaluated by independent core laboratory.	45 days
Primary	LAA Closure Rate	Rate of LAA closure defined by peri-device flow = 3mm in width per TEE evaluated by independent core laboratory.	12 months
Primary	LAA Closure Rate	Rate of LAA closure per CCTA evaluated by independent core laboratory. Contrast patency defined as LAA density =100 HU or =25% of that of the left atrium.	45 days
Primary	Composite of Ischemic Stroke or System Embolism	Composite of ischemic stroke or systemic embolism.	12 months
Secondary	Device-Related Thrombus	Rate of device-related thrombus (DRT) per CCTA evaluated by independent core laboratory.	45 days
Secondary	Device-Related Thrombus	Rate of DRT per TEE evaluated by independent core laboratory.	12 months